文献速递炎症性肠病

基线血清制瘤素M预测英夫利西单抗治疗的克罗恩病患者黏膜愈合

Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-07

研究纳入45例接受英夫利西单抗单药治疗的克罗恩病患者,第54周结肠镜评估黏膜愈合,检测基线和第14周血清制瘤素M及粪便钙卫蛋白。27例达到黏膜愈合,其制瘤素M水平在基线和第14周均显著低于未愈合者(P < 0.001),基线制瘤素M预测黏膜愈合的AUC为0.91,高于粪便钙卫蛋白的AUC 0.51(P < 0.001)。

要点

  • 45例接受英夫利西单抗单药治疗的患者中,27例第54周达到黏膜愈合。
  • 愈合者基线和第14周制瘤素M水平均显著低于未愈合者(P < 0.001)。
  • 基线制瘤素M预测黏膜愈合AUC 0.91,高于粪便钙卫蛋白AUC 0.51(P < 0.001)。

核心结论

  • 结果提示制瘤素M可预测英夫利西单抗治疗结局。
  • 与粪便钙卫蛋白相比,制瘤素M在基线的预测能力可观,提示其可作为驱动克罗恩病治疗选择的有前景生物标志物。

研究设计与样本

  • 纳入接受英夫利西单抗单药治疗的克罗恩病患者。
  • 所有患者第54周接受结肠镜评估黏膜愈合。
  • 基线及治疗第14周检测血清制瘤素M和粪便钙卫蛋白。
  • 采用Mann-Whitney检验评估制瘤素M和粪便钙卫蛋白与第54周黏膜愈合的相关性。
  • 采用曲线下面积(AUC)评估预测黏膜愈合的准确性。

主要发现

  • 共纳入45例患者,27例显示黏膜愈合。
  • 基线和第14周,黏膜愈合者的制瘤素M水平均显著低于未达到该终点者(P < 0.001)。
  • 第14周粪便钙卫蛋白水平在应答者中也低于无应答者(P < 0.001)。
  • 基线制瘤素M值与第14周制瘤素M值显著相关(Spearman相关系数=0.92,P < 0.001)。
  • 基线制瘤素M预测黏膜愈合的AUC=0.91,大于粪便钙卫蛋白的AUC=0.51(P < 0.001)。

关键数值与推荐

  • 基线制瘤素M预测黏膜愈合的AUC=0.91。
  • 基线粪便钙卫蛋白预测黏膜愈合的AUC=0.51。
  • 基线制瘤素M与第14周制瘤素M的Spearman相关系数=0.92(P < 0.001)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oncostatin M is upregulated in Crohn's disease inflamed intestinal mucosa, and has been suggested as a promising biomarker to predict responsiveness to anti-TNF therapy in patients with inflammatory bowel diseases. AIM: To evaluate the suitability of serum oncostatin M as a predictive marker of response to infliximab in Crohn's disease. METHODS: We included patients treated with infliximab monotherapy. All patients underwent colonoscopy at week 54 to evaluate mucosal healing. Serum oncostatin M and faecal calprotectin were measured at baseline and after 14 weeks of treatment. Mann-Whitney test was used to evaluate correlation of oncostatin M and faecal calprotectin at baseline and week 14 with mucosal healing at week 54. Their accuracy in predicting mucosal healing was assessed by area under the curve (AUC). RESULTS: In a cohort of 45 included patients, 27 displayed mucosal healing. At both baseline and week 14, oncostatin M levels were significantly lower in patients with mucosal healing than in patients not achieving this endpoint (P < 0.001). Faecal calprotectin levels at week 14 were lower also in responders than nonresponders (P < 0.001). Oncostatin M values at baseline and week 14 were significantly associated (Spearman correlation = 0.92, P < 0.001). The diagnostic accuracy of oncostatin M at baseline in predicting mucosal healing (AUC = 0.91) was greater than faecal calprotectin (AUC = 0.51, P < 0.001). CONCLUSION: These results suggest that oncostatin M can predict the outcome of infliximab treatment. Compared with faecal calprotectin, the predictive capability of oncostatin M was appreciable at baseline, thus indicating oncostatin M as a promising biomarker for driving therapeutic choices in Crohn's disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020. PMID: 32506635. doi:10.1111/apt.15870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。